Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.
Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G. Kaufmann M, et al. Among authors: piscitelli g. J Clin Oncol. 2000 Apr;18(7):1399-411. doi: 10.1200/JCO.2000.18.7.1399. J Clin Oncol. 2000. PMID: 10735887 Clinical Trial.
Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial.
Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Cervek J, Fowst C, Polli A, Di Salle E, Massimini G, Piscitelli G. Kaufmann M, et al. Among authors: piscitelli g. Eur J Cancer. 2000 Sep;36 Suppl 4:S86-7. doi: 10.1016/s0959-8049(00)00240-9. Eur J Cancer. 2000. PMID: 11056333 Clinical Trial.
Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study.
Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G. Kaufmann M, et al. Among authors: piscitelli g. Clin Breast Cancer. 2000 Sep;1 Suppl 1:S15-8. doi: 10.3816/cbc.2000.s.003. Clin Breast Cancer. 2000. PMID: 11970744 Clinical Trial.
Exemestane experience in breast cancer treatment.
Lønning PE, Paridaens R, Thürlimann B, Piscitelli G, di Salle E. Lønning PE, et al. Among authors: piscitelli g. J Steroid Biochem Mol Biol. 1997 Apr;61(3-6):151-5. J Steroid Biochem Mol Biol. 1997. PMID: 9365185 Review.
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group.
Thürlimann B, Paridaens R, Serin D, Bonneterre J, Roché H, Murray R, di Salle E, Lanzalone S, Zurlo MG, Piscitelli G. Thürlimann B, et al. Among authors: piscitelli g. Eur J Cancer. 1997 Oct;33(11):1767-73. doi: 10.1016/s0959-8049(97)00283-9. Eur J Cancer. 1997. PMID: 9470830 Clinical Trial.
Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group.
Webster J, Piscitelli G, Polli A, D'Alberton A, Falsetti L, Ferrari C, Fioretti P, Giordano G, L'Hermite M, Ciccarelli E, et al. Webster J, et al. Among authors: piscitelli g. Clin Endocrinol (Oxf). 1992 Dec;37(6):534-41. doi: 10.1111/j.1365-2265.1992.tb01485.x. Clin Endocrinol (Oxf). 1992. PMID: 1286524 Clinical Trial.
The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group.
Webster J, Piscitelli G, Polli A, D'Alberton A, Falsetti L, Ferrari C, Fioretti P, Giordano G, L'Hermite M, Ciccarelli E, et al. Webster J, et al. Among authors: piscitelli g. Clin Endocrinol (Oxf). 1993 Sep;39(3):323-9. doi: 10.1111/j.1365-2265.1993.tb02372.x. Clin Endocrinol (Oxf). 1993. PMID: 7900937 Clinical Trial.
34 results